throbber
Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`G Mani etal Biomaterials 312010 53725384
`
`5373
`
`1
`
`for
`
`1
`
`to
`
`than
`
`categories physical and chemical modification of stent surfaces
`The physical modification of stents includes porous textured and
`reservoir surfaces 26 The chemical modification includes the use
`of molecular coatings such as selfassembled monolayers 2223
`sizes of pores nanopores
`Porous
`stents with different
`100 nm micropores
`to 100 pm macropores
`greater
`100 pm have been created
`loading and releasing the drugs
`directly from stent surfaces 21 Nanoporous surfaces have been
`created by coating the stents first with a thin layer of aluminum
`conversion of aluminum to nano
`followed by electrochemical
`porous aluminum oxide 16 However
`the particle debris liberated
`reac
`from such ceramic coated stents has caused serious adverse
`tions in an animal model 27 Nanoporous metals 28 and carbon
`coatings 18 have
`carbon nanoparticle
`been previously
`also
`explored for delivering drugs directly from stent surfaces Micro
`have been created on stents by sandblasting
`textured surfaces
`treatment 17 Although the clinical performance of sandblasted
`stents is encouraging the on site loading of drugs in clinics prior to
`implantation may not be a favorable approach Reservoir
`stent
`surfaces have been created by laser cut holes on stent struts and the
`holes were subsequently filled with drugs However
`the clinical
`outcomes of such stents were not significantly different
`control groups 20 The use of selfassembled monolayers for
`delivering drugs from metal surfaces is also promising 2223 and
`under
`relevant
`for delivering
`currently
`investigation
`clinically
`amount of drugs Although a few limitations have to be overcome in
`these non polymer based DES still
`the successful
`these
`use of
`
`from their
`
`systems provide promising alternative approaches
`to currently
`available adverse reaction inducing polymer coated DES The goal
`of this study is to coat drug directly on metal surfaces without using
`for a period of time In this way once
`any carriers and to release it
`the drug is delivered the underlying metal substrates may not
`create adverse
`responses The tolerability of metals in coronary
`arteries with no serious adverse
`reactions has long been estab
`
`lished 2932
`Some therapeutic drugs naturally have strong adhesion towards
`certain material surfaces 3336 Paclitaxel PAT is one such drug
`restenosis 37
`which is also commonly used for treating instent
`PAT has been shown to strongly adsorb onto different materials
`including glass 35 polypropylene 35 silicones 35 and poly
`tetrafluoroethylene 38 In this study we have explored the use of
`these molecules directly on
`strong adhesion property of PAT to coat
`CoCr alloy a material which is used for making ultrathin stent
`struts and have investigated the in vitro drug release profiles of this
`system for up to 56 days
`
`2 Materials and methods
`
`The CoCrWNi alloy substrate L605 grade was purchased from High Tech
`Metals Inc Sylmar CA Absolute ethanol 200 proof methylene chloride acetone
`and methanol were all purchased from PharmoAAPER USA and used as received
`Paclitaxel >99 purity was purchased from ChemieTek Indianapolis USA HPLC
`and methanol were purchased from Sigma Aldrich USA
`grade water acetonitrile
`
`21 Preparation of cobaltchromium alloy specimens
`
`The CoCr alloy substrate was cut into 1 cm X 1 cm specimens
`The specimens
`twice for ten minutes
`were cleaned by sonication in ethanol acetone and methanol
`each Fresh solvents were used each time The specimens were then dried using N2
`gas Thus chemically cleaned CoCr alloy specimens are referred to here as control
`CoCr
`
`22 Direct coating of paclitaxel on CoCr alloy
`
`for 1 minute to remove the
`by air drying Thus prepared
`referred
`
`to here as Group A
`
`specimens were then sonicated in 2 mL of ethanol
`weakly bound drug from the alloy surfaces followed
`coated alloy specimens are henceforth
`paclitaxel
`Another
`coated alloy specimens was prepared according to the
`set of paclitaxel
`method described above but were transferred
`to an oven for heat treatment before
`ethanol
`The specimens were heated in air at 120 ° C for 12 hours The
`cleaning
`for 1 hour before cleaning them in
`specimens were then cooled in ambient air
`ethanol
`for 1 minute under sonication followed by air drying Thus prepared spec
`imens are referred to here as Group B The only difference between Group A and
`Group B was the introduction of heating step in Group B before ethanol cleaning
`Control specimens for both Groups A and B were also prepared and are referred to
`here as Groups C and D respectively For Groups C and D the alloy specimens were
`subjected to drug deposition protocols described for Groups A and B respectively
`cleaning procedure A schematic of the
`but without employing the final ethanol
`of specimens of Groups A B C and D are shown in Fig I The
`preparation
`of specimens of Groups A to D are provided in detail
`
`description
`
`in Table I
`
`23 Drug elution studies
`Specimens 4 each of Groups A B C and D were incubated in 2 mL of phos
`phate buffered saline with 005 tween20 PBST20 pH = 74 at 37 C Tween20
`was added to increase the
`solubility of paclitaxel
`respective time
`in PBS 1391 After
`points 1 3 5 7 14 28 and 56 days the alloy specimens were taken out and
`to 2 mL of fresh PBST20
`solution The PBST20
`immediately transferred
`samples
`collected at different time points were then analyzed for the quantity of drug
`1 mL of ethanol was added to PBST
`released using HPLC It
`is important to note that
`20 sample containers polypropylene tubes and vigorously shaken before analyzing
`the samples in HPLC This was done in order to avoid any potential
`drug loss to
`surfaces as reported in other studies 1351 Alcohol based
`container
`polypropylene
`used in the literature to extract
`the drug bound to the
`washing was previously
`container
`surfaces 1361 Besides the addition of ethanol
`further increases the solu
`in PBST20 and improves accuracy for the quantification
`bility of paclitaxel
`eluted using HPLC
`
`of drug
`
`231 Highperformance
`liquid chromatography
`The HPLC analysis was carried out using a Waters 2695 separations module with
`A Nova Pak®
`Waters
`2487 Dual
`A Absorbance
`Detector
`C18
`column
`
`39 mm X 150 mm particle size 4 um Part WAT086344 Serial 111937081140
`of water and acetonitrile 4555 vv was
`77 was used A mobile phase composition
`used at a flow rate of 10 mLmin A 10 iL volume of the sample was injected for
`separations were carried out at 35 C The detector
`analysis and chromatographic
`wavelength was fixed at 227 nm
`A standard stock
`solution of Paclitaxel was prepared in absolute ethanol 200
`proof at a concentration of 1 mgmL This solution was further diluted with ethanol
`range 1 ngmL to
`and working
`solutions were prepared over a wide concentration
`1099 ngmL Standard calibration curves were obtained for working solutions and the
`curve s were linear over the ranges of 199 ngmL and 991099 ngmL with correlation
`coefficients of R2 = 09996 and R2 = 09677 respectively
`data
`The chromatographic
`collected were analyzed using a Waters Millennium 32 software data system The
`calibration graphs were constructed by plotting the concentration of paclitaxel ngmL
`on the xaxis and the area of the peak microvoltssec on the yaxis
`
`24 Surface characterization
`Specimens of Groups A B C and D were characterized
`using Xray photoelec
`tron spectroscopy XPS scanning electron microscopy SEM and atomic
`force
`microscopy AFM
`
`241 Xray photoelectron spectroscopy
`XPS measurements were performed on a Kratos Axis Ultra instrument using
`Al Ka Xray source E = 14867 eV 225 W a hemispherical
`a monochromatized
`
`and a channeltron
`detector array Survey spectra were
`electron energy analyzer
`recorded with a pass energy of 160 eV while the high resolution spectra were
`recorded with a pass energy of 20 eV for 0 Is and C Is spectra or 40 eV for Co 2 p
`Cr 2 p W 4f Ni 2 p and N Is spectra All measurements were carried out using
`a nominal photoelectron
`to the sample surface The
`takeoff angle of 90° with respect
`binding energy BE values for CoCr alloy specimens before and after the coating of
`the standard hydrocarbon C Is peak at 285 eV
`paclitaxel were corrected by setting
`The spectral deconvolution
`and peak area analysis were carried out using the Casa
`XPS software system to determine the elemental and component compositions The
`atomic
`BE values
`compositions and molar percentage
`reported
`percentage
`concentrations
`the average of three distinct
`spots on each
`of components
`represent
`standard deviations
`sample along with the corresponding
`
`A solution of paclitaxel was prepared in ethanol at a concentration of 1 mg1 mL
`A 25 uL aliquot of the prepared solution was placed on the surface of each chemically
`cleaned CoCr alloy specimen using a micropipette and the specimens were stored
`under ambient laboratory conditions The ethanol was allowed to evaporate in air
`The
`a residue of paclitaxel
`for 3 hours leaving behind
`on the alloy specimens
`
`242 Scanning electron microscopy
`A ZEISS EVO40 Germany model SEM instrument was used in this study The
`images were acquired using a working distance of 3537 mm and an accelerating
`voltage of 5 kV Prior to SEM imaging the specimens were sputter coated with a thin
`layer of carbon
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`5374
`
`G Mani et al Biomaterials 312010 53725384
`
`Chemically cleaned CoCr
`
`Micropipette
`
`Paclitaxel
`
`in Ethanol
`1 mgmL
`
`Chemically cleaned
`CoCr
`
`25 ill micropipette
`
`25 ktl ethanol solution
`of Paclitaxel
`
`Ethanol evaporates
`room temperature
`
`3 hours
`
`1
`
`Paclitaxel deposit
`after ethanol evaporation
`
`CoCr
`
`No heat treated
`
`Ethanol cleaned
`
`Heat treated
`
`Ethanol cleaned
`
`No heat treated
`Not ethanol cleaned
`
`Heat treated
`
`Not Ethanol cleaned
`
`Lf
`
`Group A
`
`Group C
`Fig 1 Schematic of preparation of paclitaxel coated cobaltchromium alloy specimens of Group A B C and D
`
`Group B
`
`Group D
`
`243 Atomic force microscopy
`All AFM images were
`instrument Digital
`acquired with a Nanoscope III
`Instruments Inc Santa Barbara CA at room temperature
`in air The images were
`captured in tapping mode using Si3N4
`cantilevers with a spring constant of
`2080 Nm All the reported images were flattened using a third degree polynomial
`fit The rootmean square RMS roughness values were calculated from the average
`of at least four distinct spots 10 pm x 10 pm on two different samples and reported
`standard deviations
`here with their corresponding
`
`Table 1
`
`Descriptions of control CoCr and paclitaxel coated CoCr specimens of Groups A
`B C and D
`
`Sample Name
`Control CoCr
`
`Description
`
`Chemically
`
`cleaned cobaltchromium alloy specimens
`
`Paclitaxel coated CoCr alloy
`
`Sample Name
`
`Group A
`Group B
`Group C
`Group D
`
`Paclitaxel coated
`25 ligcm2
`
`Heat treated
`
`120 °C 12 hours
`
`Ethanol
`
`cleaned
`
`Yes
`
`Yes
`
`Yes
`
`Yes
`
`No
`
`Yes
`No
`
`Yes
`
`Yes
`
`Yes
`No
`No
`
`25 Statistical
`
`analysis
`
`data collected are presented as the mean
`The experimental
`tion A oneway analysis of variance ANOVA was performed
`significance for difference was defined as p < 005
`
`standard devia
`
`and statistical
`
`3 Results
`
`31 Delivery of paclitaxel from CoCr alloy
`
`The initial drug loaded on CoCr alloy specimens of Groups A B
`C and D was 25 ugcm2 After drug deposition the specimens of
`Groups A and B were cleaned
`in ethanol
`to remove the weakly
`bound drug from the alloy surfaces The ethanol solution used for
`cleaning was then analyzed in HPLC to calculate the amount of drug
`washed out during the cleaning protocols Table 2 The difference
`drug loaded 25 ug and the amount of drug
`between the initial
`washed out
`in ethanol provided the amount of drug that actually
`retained on the alloy surface after ethanol cleaning or before
`immersion in PBST20 media Approximately 20 and 25 of the
`initial drug loaded was retained on the alloy surfaces after ethanol
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`G Mani etal Biomaterials 312010 53725384
`
`5375
`
`0 Group A
`sGroupB
`
`a
`
`400
`
`350
`
`300
`
`a
`
`11
`
`cs7 250
`E
`
`_

`1_ T
`
`10
`
`20
`
`30
`
`40
`
`60
`
`60
`
`Days
`
`Group A
`Group B
`
`10
`
`20
`
`30
`
`40
`
`50
`
`60
`
`200
`
`150
`
`100
`
`50
`
`0
`
`8 7 6
`
`4 3 2 1 0
`
``1
`
`133
`
`a
`13
`
`_
`
`O 6
`wO cn
`110
`
`702
`
`0
`
`Days
`of specimens of Groups A and B b Percentage
`Fig 2 a In vitro drug release
`of total drug release profiles of specimens of Groups A and B
`
`profiles
`
`This suggests that once the loosely bound PAT is removed by solvent
`cleaning as in Groups A and B or burst released as in Groups C and
`D the remaining strongly bound PAT molecules will be slowly
`released over a period of time
`The control CoCr alloy and four groups A B C and D of drug
`coated specimens were thoroughly characterized using SEM AFM
`and XPS to study the morphology distribution and attachment of
`PAT on CoCr alloy specimens
`
`32 SEM characterization
`
`Fig 5af shows the SEM images of control CoCr alloy and PAT
`coated CoCr alloy specimens A flat
`surface was observed
`control CoCr alloy with few surface pits Two different
`forms of
`paclitaxel crystals spheres Fig 5b and e and needles Fig Sc
`were formed on the specimens of Groups C and D The SEM images
`in determining the shape and distribution of
`are particularly useful
`aggregates of PAT molecules crystals on the specimens of Groups
`C and D Fig 5b c and e However
`the resolution of SEM limited
`imaging the molecular distribution of PAT molecules on the spec
`imens Fig 5d and f
`
`for
`
`33 AFM characterization
`
`The AFM tapping mode height and amplitude images of control
`and PAT coated CoCr alloy specimens are shown in Fig 6aj The
`
`Table 2
`Amount of drug retained on CoCr alloy specimens of Groups A and B after ethanol
`cleaning
`
`in
`
`Initial drug loaded
`Amount of drug washed out
`ethanol cleaning procedure
`Total amount of drug retained on
`the alloy surface after ethanol cleaning
`Amount of
`Initial drug loaded
`drug washed out
`in ethanol
`Percentage of total amount of
`drug washed out
`in ethanol cleaning
`Percentage of total amount of
`drug loaded on the alloy surface
`after ethanol cleaning
`
`Group
`
`25 jig
`202
`
`A
`
`07 jig
`
`Group
`
`B
`
`25 jig
`188 L03 jig
`
`48
`
`07 jig
`
`62
`
`03 jig
`
`81 3
`
`1913
`
`751 L12
`
`249 12
`
`cleaning of specimens of Groups A and B respectively The amount
`of drug that was
`retained on the specimens of Group B was
`significantly p <005 greater than that of Group A This suggests
`the heating treatment
`improves the stability of paclitaxel on
`that
`CoCr alloy surfaces
`Fig 2a shows the drug release profiles of Groups A and B in PBS
`T20 solution A sustained release profile was observed
`for both
`Groups A and B for up to 56 days The total amount of drug released
`significant between all consecutive
`was statistically
`time points
`from day 1 to day 56 for both Groups A and B Fig 2a Fig 3a
`the actual amount of drug released
`between every two
`shows
`consecutive
`time points and clearly demonstrates that paclitaxel
`was released from CoCr alloy surfaces in a sustained manner The
`actual amount of drug released
`from specimens of Group B was
`significantly lower than that of the specimens of Group A on day1
`and between days 3 and 5 Fig 3a This led to the release of less
`total drug from the specimens of Group B when compared to that of
`Group A for up to 7 days Fig 2a No statistically
`significant
`difference in the total amount of drug released was observed
`between Groups A and B from day 14 to day56 This suggests that
`a simple heating protocol provides improved stability of PAT on
`CoCr alloy surfaces This effect
`is especially significant during the
`immersion in PBST20 which cause PAT to be
`days of
`delivered from heated specimens Group B at a slower
`rate than
`unheated specimens Group A Fig 2b shows
`the percentage
`total drug release profiles for Groups A and B Approximately 7
`and 5 of the total drug retained after ethanol cleaning
`was
`from Groups A and B respectively for up to 56 days This
`suggests that PAT strongly adhered to CoCr alloy surfaces and only
`a limited amount of the total drug retained can be released for the
`time period investigated in this study
`Fig 4a shows the drug release profiles of Groups C and D PAT
`coated CoCr specimens which were not cleaned in ethanol
`in PBS
`T20 solution Burst release profiles were observed for both Groups
`C and D No significant difference in the total amount of drug
`from day 1 to day56 Approximately
`was observed
`7080 of the total drug loaded was released within day 1 and 90
`of the total drug was released in 56 days It
`is interesting to note that
`10 of the total drug loaded was retained on the alloy surface even
`of drug retained on the surface was
`after 56 days The percentage
`based on the difference between the total drug loaded
`calculated
`and the amount of drug released
`for up to 56 days The actual
`between every two consecutive
`amount of drug released
`time
`points of specimens of Groups C and D are shown in Fig 4b A
`significant amount of drug was burst released within the first 3 days
`followed by a slow and sustained release for up to 56 days Inter
`estingly the actual amounts of drug released from the specimens of
`Groups C and D after 7 days are in the same range as the amount
`from Groups A and B 48 nanogramsday
`of drug released
`
`initial
`
`released
`
`released
`
`of
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`G Mani et al Biomaterials 312010 53725384
`
`pGroupA
`r Group B
`
`a
`
`sGroupC
`NGroupD
`
`25
`
`20
`
`2
`
`a o
`
`_
`
`ol 15
`E
`o u
`E
`
`10
`
`Nb45
`4 <
`co°
`k
`
`ttlwfi°
`69
`
`b0
`
`e°
`
`t
`
`5
`
`0
`
`10
`
`20
`
`30
`
`Days
`
`40
`
`50
`
`60
`
`Group C
`0GroupD
`
`100
`
`90
`
`ra
`
`a
`
`n0
`
`3
`
`25
`
`4
`
`ec
`13
`
`016
`46 6
`
`eiP6
`
`eep
`
`°36
`
`ezzi
`°fob
`
`e 6
`
`oc°
`
`5376
`
`a
`
`140
`
`120
`
`3
`
`41c
`
`100
`
`2_ 5 80
`o
`
`60
`
`_
`
`o 58
`
`2
`
`40
`
`_9
`
`20
`
`25
`
`ENT
`
`16
`
`20
`
`10
`
`20
`
`30
`
`46
`
`50
`
`50
`
`F
`
`13
`
`2
`
`o
`
`ac
`
`_
`c
`
`80
`
`70
`
`60
`
`50
`
`40
`
`30
`
`20
`
`10
`
`Os
`0
`
`9
`
`a
`
`g
`
`f a_
`
`o
`
`a g
`
`0
`
`2
`
`15
`
`1
`
`05
`
`_ Group C
`Group D
`
`6
`
`4a4f
`po b
`Lev
`ose
`
`aeo
`
`3 4466
`
`cri
`
`E 15
`00
`
`g
`
`zz 10
`
`5
`
`0
`
`45 0
`
`c u
`
`e5A
`
`ke 671 t
`
`Ncs
`
`be
`
`6c
`
`Nb`
`
`rs
`
`Fig 3 Amount of drug eluted between every two consecutive time points of Groups A
`and B a and Groups C and D b
`
`control CoCr showed flat
`topography with few pits and surface
`defects Fig 6a and b The RMS roughness value of control CoCr
`was 196 ± 73 nm The formation of sphere and needle shaped PAT
`crystals on CoCr was clearly observed in Groups C and D Fig 6c d
`g and h The RMS roughness values of the specimens of Groups C
`and D were 2823 ± 527 nm and 1486 ± 457 nm respectively This
`increase in surface roughness values demonstrated the
`significant
`on CoCr alloy These results are
`presence of drug aggregates
`qualitatively consistent with SEM images AFM images were also
`in observing the molecular distribution of PAT on the spec
`useful
`imens of Groups A and B Fig 6e f i and j The RMS roughness
`values of the specimens of Groups A and B were 240 ± 122 nm and
`162 ± 58 nm respectively
`
`34 XPS characterization
`
`The high resolution XPS C Is 0 Is N Is Co 2p Cr 2p W 4f and
`Ni 2p spectra were collected before and after the deposition of PAT
`on CoCr alloys The chemical compositions of control CoCr alloy
`and PAT coated CoCr alloys Groups A and C are shown in Fig 7a
`When compared to control CoCr the specimens of Group C
`showed a significant
`increase in the concentration of carbon and
`a significant decrease
`in the concentrations of oxygen and other
`
`Days
`Fig 4 a In vitro drug release profiles of specimens of Groups C and D b Percentage
`of total drug release profiles of Group C and D
`
`elements Co Cr W and Ni specific to the alloy substrate Since the
`
`PAT contains 47 carbon atoms the concentration
`of carbon is
`expected to increase after the drug deposition Also when the drug
`is deposited on the alloy the concentrations of oxygen the main
`in the surface oxides of CoCr alloy and other elements in
`element
`the alloy substrate are expected to decrease due to attenuation of
`XPS signals Such increases
`in the concentration of carbon and
`decreases in the concentrations of oxygen and other elements are
`less in Group A when compared to Group C However
`is imper
`the concentration of carbon in Group A is
`ative to note that
`significantly greater than that of control CoCr and the decrease in
`the concentrations of oxygen and other elements is significantly
`lower than that of control CoCr This strongly suggests that after
`ethanol cleaning some PAT molecules are still
`strongly adsorbed
`onto CoCr alloy surfaces Similar results were also observed
`for
`specimens of Groups D and B Fig 7b
`a trace of nitrogen
`Besides the unavoidable carbon contaminant
`contaminant was also observed on control CoCr Similar contami
`nation was reported by several other research groups for metal oxide
`samples 4041 A ratio of carbon to elements in the underlying
`metal substrate has been used in the literature to precisely determine
`of organic molecules on metal substrates
`
`the adsorptiondesorption
`
`it
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`G Mani etal Biomaterials 312010 53725384
`
`5377
`
`irk roupC spherical crystals
`
`10 umII
`
`EMT
`W0
`
`5 09 kV
`
`16
`
`nrn
`
`4thg
`
`300KX
`
`R028531f
`
`UTSA
`
`EMT
`
`5 ODIN
`
`vi0 15 5orn
`
`lisp 303 0
`
`roe Ita0c = PL 2312 LI
`
`UTSA
`
`d Group A
`
`10 µ
`
`EHT
`WD
`
`5 00 kV
`
`350tnro
`
`Hogg 100K
`P262 V
`Ede Name
`
`e Group D spherical crystals
`
`EHT
`WD
`
`500 kV
`
`355 rffn
`
`1144g
`
`3 OD K
`Fie Name RN 30 62of
`
`UTSA
`
`EHT
`
`50014V
`
`Mac
`
`300K X
`RP 47143 NI
`
`Fds ftwre
`
`WE 35 5 arm
`mages of control CoCr alloy a group C spherical crystals b group C needle crystals c group A d group D spherical crystals e group B f
`
`UTSA
`
`IQ I
`
`EHT
`
`SCOW
`
`413
`
`37 0
`
`OCIKX
`
`FI103r
`
`HTer RP44 01
`
`UTSA
`
`Fig 5 SEM
`
`for all
`
`4245 We used such an approach
`to determine the adsorption of
`PAT on CoCr alloys Since ample amount of carbon and oxygen
`the ratios of the concentration of
`atoms are present
`in paclitaxel
`these elements to the concentrations of cobalt chromium tungsten
`and nickel were calculated to qualitatively determine the presence of
`PAT on CoCr alloys A ratio of carbon to oxygen was also calculated
`the specimens Fig 8a shows CCo + Cr + W Ni 0
`Co + Cr + W Ni and CO ratios of control CoCr and Groups A and
`C All the three ratios calculated for Group A were greater than that of
`control and lower than that of Group C This further confirms the
`presence of strongly bound PAT molecules on CoCr alloy after
`ethanol cleaning As expected the ratios were highest for Group C
`due to the presence of aggregates of drug Similar results were also
`observed for the specimens of Groups B and D Fig 8b
`The high resolution XPS C Is spectrum of control CoCr alloy
`the peaks at 285 eV
`was deconvoluted into three components
`2861 eV and 2886 eV were assigned to CC C0 and C=0 bonds
`of hydrocarbon contaminants Fig 9a and Table 3a Several studies
`in the literature have reported the adsorption of such contaminants
`on metal oxide surfaces 4546 Also the C Is peak of hydrocarbon
`
`contamination
`
`used
`
`as an internal
`
`standard for
`
`is commonly
`calibration 46 The C Is spectrum of paclitaxel in
`instrument
`form was deconvoluted into four components
`the peaks
`powder
`of the components at 285 eV 2866 eV 2892 eV and 2916 eV were
`to carbon atoms in hydrocarbon hydroxyl ester and
`assigned
`aromatic ring groups of PAT Fig 9b and Table 3a The C Is spectra
`of Groups C and D were deconvoluted into four components
`the
`peaks of the components C Is 1 C Is 2 C Is 3 and C Is 4
`were observed at 285 eV between 2864 and 2869 between 2884
`and 2889 and between 2904 and 2912 eV respectively C Is 1
`was assigned to CC bonds of PAT C Is 2 was assigned to COH
`bonds of PAT C ls 3 was assigned to 0=C0 bonds of PAT and C
`Is 4 was assigned to it > it
`shakeup satellite from the aromatic
`rings of PAT Thus the C Is components of Groups C and D are in
`excellent agreement with the C Is components of PAT powder For
`
`Groups A and B the components C Is 1 C Is 2 and C Is 3
`observed were similar to that of Groups C and D However
`4 component was missing in both Groups A and B Fig 9a and
`Table 3a This could be due to the lesser amount of drug present on
`these specimens 22
`
`the C Is
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`5378
`
`G Mani et al Biomaterials 312010 53725384
`
`a Control CoCr
`height image
`
`b Control CoCr
`amplitude image
`
`100
`
`20v
`
`=WIZ
`
`111U
`
`d GroupC
`amplitude image
`
`f Group A
`amplitude image
`
`46tt
`is 481011
`
`ri4P
`41
`IP
`Tr222
`WV
`
`°pep
`
`fir
`
`qp
`
`I W
`
`Pe
`
`LieciiIMApas
`
`2
`
`170aRtR
`
`771111
`
`iLE
`
`Fig 6 AFM images of control CoCr ab Group C cd Group A el Group D gh and Group B ij
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`60C
`
`IV
`
`50
`
`40 r nu
`
`N
`
`I
`
`30
`
`I
`
`20
`
`I
`
`10
`
`Fri
`
`Ii
`
`1l01
`
`a
`
`Atomicconcentration0
`
`Cis
`
`01s
`
`Nis
`
`Co 2p
`
`Cr2p
`
`W 4f
`
`Ni 2p
`
`70
`
`60
`
`Control CoCr
`
`G Ma
`
`etal Biomaterials 312010 53725384
`
`5379
`
`MConirol CoCr
`
`II
`
`Group C
`
`I
`
`Group A
`
`6
`
`5
`
`
`
`44
`
`
`
`33
`
`1
`
`
`
`00
`
`6
`
`
`
`55
`
`
`
`33
`
`
`0o
`0
`
`Fr
`Frj
`
`R
`
`L
`
`3
`
`increase
`
`properties
`
`towards different
`
`the risk of thrombosis and c delayed and incomplete
`is frequently observed 94749 Hence there is
`endothelialization
`a need to deliver drugs from stents without using polymer carriers
`In this study PAT was directly coated on CoCr alloy surfaces using
`its own strong adhesion property and the in vitro drug release
`profiles of this system were investigated
`Paclitaxel has strong binding
`material substrates such as glass polypropylene and silicone 35
`Song et al 35 examined the binding of PAT to glass and plastic
`containers in aqueous solution and tissue culture medium PAT was
`more strongly adsorbed on to glass than plastic containers Several
`other studies have also reported the adsorption of PAT on various
`plastic container
`surfaces during in vitro drug elution studies
`Palmgren et al 36 investigated the adsorption of various other
`drugs on plastic containers in deionized water and buffer solution
`Acidic drugs such as hydrochlorothiazide
`naproxen probenicid
`and indomethacin showed no adsorption on plastic containers in
`either water or buffer solution However
`basic drugs such as
`metoprolol medetomidine propranolol and midazolam strongly
`tubes especially when the storage
`adsorbed on polystyrene
`
`Control CoCr
`Group C
`Group A
`
`CCo+Cr+W+Ni
`
`0Co+CrFW+Ni
`
`CIO
`
`Control CoCr
`Group D
`Group B
`
`20
`
`18
`
`16
`
`14
`
`12
`
`10
`
`8 6 4 2
`
`ll
`
`0 r
`
`0 0 1
`
`0
`
`10
`
`10
`
`O 1
`
`0 0
`
`a
`
`ratios
`
`XPS
`
`cs
`
`771
`
`a
`
`CCo+Cr+W+Ni
`
`d0
`Fig 8 XPS determined CCo + Cr + W + Ni 0Co + Cr + W + Ni and C0 ratios of
`control Groups C and A a and Groups D and B b
`
`0Co+Cr+W+Ni
`
`Atomic
`
`concentration
`
`4
`
`3
`
`2
`
`0
`
`11 Group D
`
`Group B
`
`1
`
`I
`
`50
`
`40
`
`30
`
`20
`
`10 if
`
`Atomicconcentration
`
`Cis
`
`01s
`
`Nis
`
`W 4f
`Co 2p
`Fig 7 XPS determined atomic compositions of control Groups C and A specimens a
`and control Groups D and B specimens b
`
`Cr 2p
`
`Ni 2p
`
`The 0 Is XPS spectrum of control CoCr was deconvoluted into
`0 Is 1 at
`the peaks of
`three components
`the components
`5299 eV 0 Is 2 at 5316 eV and 0 Is 3 at 5334 eV were
`assigned to metal oxide 0i species hydroxide OH species and
`H20 species respectively Fig 9c and Table 3b The 0 Is spectrum
`form was deconvoluted into two components
`of PAT in powder
`the components at 5324 eV and 5336 eV were
`the peaks of
`assigned to oxygen atoms in OC and 0C=0 bonds respectively
`Fig 9d and Table 3b The 0 Is spectra of Groups A B C and D were
`the peaks of the compo
`all deconvoluted into three components
`nents 0 Is 1 0 Is 2 and 0 Is 3 were observed between 5299
`and 5301 between 5315 and 5322 between 533 and 5343 eV
`respectively Fig 9c and Table 3b 0 Is 1 was assigned
`to metal
`oxide species 0 Is 2 was assigned to OC bonds of PAT 0 Is 3
`to 0C=0 bonds of PAT The 0 Is components of
`was assigned
`Groups A B C and D are in good agreement with the 0 Is
`that PAT mole
`components of PAT powder These results suggest
`cules were bound to CoCr alloy surfaces
`
`4 Discussion
`
`Most currently available drug eluting stents DES in the market
`use polymerbased carriers for delivering drugs However
`there are
`a number of safety issues associated with polymerbased DES a
`hypersensitive allergic reactions 101447 b mechanical
`
`the polymers cause adverse responses including inflammatory and
`
`fissures peeling of polymer layers from the
`defects such as cracks
`have
`roughened surface with irregularities and waviness
`stent
`been observed
`in the polymer coatings of commercially available
`DES after balloon catheter expansion 48 and such defects
`can
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`5380
`
`G Mani et al Biomaterials 312010 53725384
`
`a
`
`XPS C is soectra
`
`2887 eV
`0C0
`
`2864 eV
`COH
`
`J
`
`285 eV
`
`C C
`
`b
`
`XPS C is spectra
`
`Paclitaxel powder form
`
`> 285 eV
`
`CC
`
`285 eV
`
`CC
`
`285 eV
`
`CC
`
`285 eV
`
`C C
`
`11 groupB
`
`2912 eV
`it 91t
`Shakeup satellite OC=O
`iv group D
`
`2889 eV
`
`2869 eV
`COH
`
`iii group A
`
`2887 eV
`0C=0
`
`2904 eV
`74e
`2884 eV
`satellite 0C=0
`Shakeup
`ii group C
`
`2862 eV
`
`COH t
`
`2864 eV
`C OH
`
`2886 eV
`
`C0
`
`2861 eV
`
`C0
`
`i control CoCr
`
`IntensityArbitraryUnits
`
`294
`
`292292
`
`290
`288
`286
`Binding Energy eV
`
`24
`
`282
`
`C
`
`XPS 0 is spectra
`
`530 eV
`
`4 > 02
`
`5301 eV
`01
`
`5299 eV 7
`0 2
`
`530 eV
`> 021
`
`5299 eV
`02
`
`5318 eV
`
`0C
`
`<
`
`4 5
`
`322 eV
`
`0C r
`
`5335 eV
`
`0C C
`
`v group B
`
`5343 eV
`0=C
`
`5315 eV
`533 eV
`0=c c 0CAilly
`dappp
`eV5336
`C141111r=C
`
`5315
`
`eV
`
`411111111
`
`iv grou
`
`L>
`
`i ii group A
`
`co
`
`ii group C
`
`5316 eV
`
`OH
`
`5334 eV
`H20
`i control GoCr
`
`285 eV
`
`CC
`
`2866 eV
`COH
`
`2892 eV
`0C=0
`
`2916 eV
`
`Shakeup satellite
`
`300
`
`290
`Binding Energy eV
`
`= r
`280
`
`XPS 0 is spectra
`
`L Paclitaxel powder form
`
`z
`
`6
`
`IntensityArbitraryUnits
`
`544 542 540 538 536 534 532 530 528
`Binding Energy eV
`
`538
`
`536
`
`530
`
`534
`532
`Binding Energy eV
`of control CoCr and groups A to D a C Is spectrum of
`Fig 9 XPS C Is spectra
`of paclitaxel powder form d
`
`spectra
`
`528
`
`paclitaxel powder form b 0 Is spectra
`
`of control CoCr alloy and groups A to D c and 0 Is
`
`medium was water No loss of drug has been observed
`solution and this could be attributed to buffer ions competition for
`These
`plastic surfaces which could prevent drug interactions
`the adsorption of drug on a material surface
`studies suggested that
`factors a chemical nature of the drug b
`physiochemical properties of the material surface and c solvent
`
`depends
`
`on several
`
`in buffer
`
`drug properties The storage temperature and drug concentration
`
`role in determining the adsorption properties of
`also play a critical
`a drug 50 To the best of our knowledge no reports have been
`published on the mechanism of PAT adsorption to various material
`surfaces
`The hypothesis for the direct attachment of PAT on CoCr alloy
`the drug forms extensive hydrogen bonding with metal
`is that
`oxide surfaces which have plenty of hydroxyl groups as inferred
`
`Abraxis EX2033
`Cipla Ltd. v. Abraxis Bioscience, LLC
`IPR2018-00162; IPR2018-00163; IPR2018-00164
`
`

`

`alloy surface belong to hydroxyl groups
`
`it
`
`G Mani etal Biomaterials 312010 53725384
`from the XPS 0 Is spectra 75 of oxygen atoms present on CoCr
`Table 3b The PAT
`molecules interact with each other through hydrogen bonding 51
`When the ethanol
`is allowed to evaporate after drug loading on the
`alloy surfaces the intermolecular hydrogen bonding of PAT mole
`cules drive them to form aggregates of crystals 52 as in Groups C
`and D However
`the specimens coated with aggregates of PAT
`crystals showed burst
`release in PBST20 during drug elution
`studies or ethanol during ethanol cleaning procedure This could
`in PBST20 might interfere
`be due to the reason that
`ion species
`with intermolecular hydrogen bonding of PAT molecules 53 in the
`and result
`in the release of drug crystals Organic
`aggregates
`form hydrogen bonding with PAT mole
`solvents such as ethanol
`cules and this could have caused the loss of integrity of aggregates
`of PAT However
`is interesting to observe that neither ions in PBS
`T20 nor ethanol molecules could remove all
`the PAT molecules
`that are strongly adhered to CoCr alloy surfaces This is clearly
`from the specimens of Groups A and B which showed
`evident
`a sustained release of the retained drug after the removal of drug
`crystals during ethanol cleaning Similar effect was also seen in
`Groups C and D when most of the drug crystals were released
`during the first 3 days of PBST20 immersion the remaining drug
`retained on the surface was eluted at a sustained rate for a period of
`56 days These behaviors could be due to extensive hydrogen
`bonding interactions between PAT molecules and high density
`surface hydroxyl groups of metal oxide Based on this discussion
`we hypothesize that PAT forms a molecular
`coating strongly
`bound on CoCr alloy surface and crystals of drug weakly bound
`layer Fig 10a The weakly
`on top of the strongly bound molecular
`bound crystals release quickly and cause the burst effect
`in elution
`profiles Fig 10b while the strongly bound molecules release at
`a sustained rate Fi

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket